Alexion switches to solar power
This article was originally published in Scrip
Alexion Pharmaceuticals has strengthened its green credentials by putting solar panels generating 295kW on the rooftop of its facility in Cheshire, Connecticut, which will provide 9% of its electrical needs. The system was funded by a grant from the Connecticut Clean Energy Fund. The 1,738 photovoltaic cells will reduce its carbon dioxide emissions by 380,000 lbs annually, the company estimates. Alexion markets the appropriately named product Soliris (eculizumab), for the rare and life-threatening blood disorder, paroxysmal nocturnal haemoglobinuria.